Climb Bio (CLYM) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, with a pipeline built through strategic acquisitions and in-licensing of candidates with strong biological rationale and development pathways.

• Lead product candidate is budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated diseases, initially focused on primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

• Also developing CLYM116, a next-generation anti-APRIL monoclonal antibody for IgA nephropathy and other B-cell mediated diseases, featuring Fc-engineering for enhanced efficacy.

Financial performance and metrics

• Completed a private placement on April 27, 2026, issuing 9,481,000 shares at $9.50 per share and 2,106,000 prefunded warrants at $9.4999 each, raising approximately $110 million in gross proceeds before fees and expenses.

• As of May 14, 2026, 57,263,023 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; will receive proceeds only upon cash exercise of prefunded warrants.

• Proceeds from the private placement were used to support operations and capital needs.